Exagen Expects FY2024 Revenue Of Approximately $54M Versus Consensus Of $54.14M; For FY2024, the Company Expects Adjusted EBITDA Will Be Better Than Negative $20M
Portfolio Pulse from Benzinga Newsdesk
Exagen anticipates its FY2024 revenue to be around $54M, slightly below the consensus estimate of $54.14M. Additionally, the company projects its adjusted EBITDA for FY2024 to improve, being better than negative $20M.

March 18, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Exagen expects FY2024 revenue of approximately $54M, slightly below consensus estimates, and an adjusted EBITDA better than negative $20M.
The slight miss in revenue expectations compared to consensus may slightly concern investors, but the improved outlook on adjusted EBITDA could indicate better financial health and operational efficiency than previously anticipated. This mixed outlook suggests a neutral short-term impact on the stock price, as the market digests both the slight revenue shortfall and the positive EBITDA forecast.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100